BRIEF-GRI Bio Inc - Receives Topline Data From Phase 2A Trial For Idiopathic Pulmonary Fibrosis - SEC Filing

Reuters12-08

Dec 8 (Reuters) - GRI Bio Inc GRI.O:

GRI BIO INC - RECEIVES TOPLINE DATA FROM PHASE 2A TRIAL FOR IDIOPATHIC PULMONARY FIBROSIS - SEC FILING
GRI BIO INC - TRIAL MEETS PRIMARY ENDPOINT & CERTAIN SECONDARY ENDPOINTS; GRI-0621 WELL TOLERATED - SEC FILING
GRI BIO INC - NO SAFETY OR TOLERABILITY CONCERNS IN GRI-0621 TREATED SUBJECTS - SEC FILING

Source text: [ID:n0001824293-25-000160]

Further company coverage: GRI.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589735322?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 21:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589735322","market":"nz","top_or_hot":-1,"title":"BRIEF-GRI Bio Inc - Receives Topline Data From Phase 2A Trial For Idiopathic Pulmonary Fibrosis - SEC Filing","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-GRI Bio Inc - Receives Topline Data From Phase 2A Trial For Idiopathic Pulmonary Fibrosis - SEC Filing</title></head><body><p><span>Dec 8 (Reuters)</span><span> - </span>GRI Bio Inc <span>GRI.O</span>:</p><ul><li><p><a href=\"https://laohu8.com/S/GRI\">GRI BIO INC</a> - RECEIVES TOPLINE DATA FROM PHASE 2A TRIAL FOR IDIOPATHIC PULMONARY FIBROSIS - SEC FILING</p></li><li><p>GRI BIO INC - TRIAL MEETS PRIMARY ENDPOINT &amp; CERTAIN SECONDARY ENDPOINTS; GRI-0621 WELL TOLERATED - SEC FILING</p></li><li><p>GRI BIO INC - NO SAFETY OR TOLERABILITY CONCERNS IN GRI-0621 TREATED SUBJECTS - SEC FILING</p></li></ul><p>Source text: [ID:n0001824293-25-000160]</p><p>Further company coverage: <span>GRI.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-GRI Bio Inc - Receives Topline Data From Phase 2A Trial For Idiopathic Pulmonary Fibrosis - SEC Filing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-GRI Bio Inc - Receives Topline Data From Phase 2A Trial For Idiopathic Pulmonary Fibrosis - SEC Filing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-08 21:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-GRI Bio Inc - Receives Topline Data From Phase 2A Trial For Idiopathic Pulmonary Fibrosis - SEC Filing</title></head><body><p><span>Dec 8 (Reuters)</span><span> - </span>GRI Bio Inc <span>GRI.O</span>:</p><ul><li><p><a href=\"https://laohu8.com/S/GRI\">GRI BIO INC</a> - RECEIVES TOPLINE DATA FROM PHASE 2A TRIAL FOR IDIOPATHIC PULMONARY FIBROSIS - SEC FILING</p></li><li><p>GRI BIO INC - TRIAL MEETS PRIMARY ENDPOINT &amp; CERTAIN SECONDARY ENDPOINTS; GRI-0621 WELL TOLERATED - SEC FILING</p></li><li><p>GRI BIO INC - NO SAFETY OR TOLERABILITY CONCERNS IN GRI-0621 TREATED SUBJECTS - SEC FILING</p></li></ul><p>Source text: [ID:n0001824293-25-000160]</p><p>Further company coverage: <span>GRI.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE10C:1","article_id":"2589735322","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589735322","pubTimestamp":1765199673,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-GRI Bio Inc - Receives Topline Data From Phase 2A Trial For Idiopathic Pulmonary Fibrosis - SEC FilingDec 8  - GRI Bio Inc GRI.O:GRI BIO INC - RECEIVES TOPLINE DATA FROM PHASE 2A TRIAL FOR IDIOPATHIC PULMONARY FIBROSIS - SEC FILINGGRI BIO INC - TRIAL MEETS PRIMARY ENDPOINT & CERTAIN SECONDARY ENDPOINTS; GRI-0621 WELL TOLERATED - SEC FILINGGRI BIO INC - NO SAFETY OR TOLERABILITY CONCERNS IN GRI-0621 TREATED SUBJECTS - SEC FILINGSource text: [ID:n0001824293-25-000160]Further company coverage: GRI.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GRI":"GRI BIO INC","BK4007":"制药"},"translate_title":"简介-GRI Bio Inc-收到特发性肺纤维化2A期试验的顶线数据-SEC备案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GRI":0.9},"content_text":"BRIEF-GRI Bio Inc - Receives Topline Data From Phase 2A Trial For Idiopathic Pulmonary Fibrosis - SEC FilingDec 8 (Reuters) - GRI Bio Inc GRI.O:GRI BIO INC - RECEIVES TOPLINE DATA FROM PHASE 2A TRIAL FOR IDIOPATHIC PULMONARY FIBROSIS - SEC FILINGGRI BIO INC - TRIAL MEETS PRIMARY ENDPOINT & CERTAIN SECONDARY ENDPOINTS; GRI-0621 WELL TOLERATED - SEC FILINGGRI BIO INC - NO SAFETY OR TOLERABILITY CONCERNS IN GRI-0621 TREATED SUBJECTS - SEC FILINGSource text: [ID:n0001824293-25-000160]Further company coverage: GRI.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589735322","isCrawlerRequest":true}